BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38156615)

  • 1. Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.
    Zheng L; Aimaiti Z; Long L; Xia C; Wang W; Zhou ZZ
    J Med Chem; 2024 Jan; 67(1):728-753. PubMed ID: 38156615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.
    Rodriguez WE; Wahlang B; Wang Y; Zhang J; Vadhanam MV; Joshi-Barve S; Bauer P; Cannon R; Ahmadi AR; Sun Z; Cameron A; Barve S; Maldonado C; McClain C; Gobejishvili L
    Hepatology; 2019 Dec; 70(6):1958-1971. PubMed ID: 31081957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical evidence for suppression of alcohol intake by apremilast.
    Grigsby KB; Mangieri RA; Roberts AJ; Lopez MF; Firsick EJ; Townsley KG; Beneze A; Bess J; Eisenstein TK; Meissler JJ; Light JM; Miller J; Quello S; Shadan F; Skinner M; Aziz HC; Metten P; Morrisett RA; Crabbe JC; Roberto M; Becker HC; Mason BJ; Ozburn AR
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36656645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Inhibition of PDE4B Reduces Binge Drinking in Two C57BL/6 Substrains.
    Jimenez Chavez CL; Bryant CD; Munn-Chernoff MA; Szumlinski KK
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34064099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
    Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
    Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.
    Song Z; Huang YY; Hou KQ; Liu L; Zhou F; Huang Y; Wan G; Luo HB; Xiong XF
    J Med Chem; 2022 Mar; 65(5):4238-4254. PubMed ID: 35188767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy.
    Tarli C; Mirijello A; Addolorato G
    Semin Liver Dis; 2022 May; 42(2):138-150. PubMed ID: 35292951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats.
    Wen RT; Zhang M; Qin WJ; Liu Q; Wang WP; Lawrence AJ; Zhang HT; Liang JH
    Alcohol Clin Exp Res; 2012 Dec; 36(12):2157-67. PubMed ID: 22671516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.
    Lee JS; Mukhopadhyay P; Matyas C; Trojnar E; Paloczi J; Yang YR; Blank BA; Savage C; Sorokin AV; Mehta NN; Vendruscolo JCM; Koob GF; Vendruscolo LF; Pacher P; Lohoff FW
    Sci Rep; 2019 Nov; 9(1):17167. PubMed ID: 31748600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifetime drinking history in patients with alcoholic liver disease and patients with alcohol use disorder without liver disease.
    Nielsen JK; Olafsson S; Bergmann OM; Runarsdottir V; Hansdottir I; Sigurdardottir R; Björnsson ES
    Scand J Gastroenterol; 2017; 52(6-7):762-767. PubMed ID: 28276826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents.
    Gong MF; Wen RT; Xu Y; Pan JC; Fei N; Zhou YM; Xu JP; Liang JH; Zhang HT
    Psychopharmacology (Berl); 2017 Oct; 234(20):3143-3151. PubMed ID: 28748375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel 3-Amino-4-alkoxyphenylketones as PDE4 Inhibitors with Improved Oral Bioavailability and Safety against Spatial Memory Impairments.
    Xia C; He JP; Feng KW; Liu L; Zheng L; Wang HT; Xu JP; Zhou ZZ
    ACS Chem Neurosci; 2022 Feb; 13(3):390-405. PubMed ID: 35050567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of phosphodiesterase-4 decreases ethanol intake in mice.
    Hu W; Lu T; Chen A; Huang Y; Hansen R; Chandler LJ; Zhang HT
    Psychopharmacology (Berl); 2011 Nov; 218(2):331-9. PubMed ID: 21509503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.
    Green EW; Byers IS; Deutsch-Link S
    Clin Ther; 2023 Dec; 45(12):1189-1200. PubMed ID: 38052695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary Care of Alcohol-related Liver Disease and Alcohol Use Disorder: A Narrative Review for Hepatology and Addiction Clinicians.
    Shroff H; Gallagher H
    Clin Ther; 2023 Dec; 45(12):1177-1188. PubMed ID: 37813775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apremilast-induced increases in acute ethanol intoxication and decreases in ethanol drinking in mice involve PKA phosphorylation of GABA
    Blednov YA; Da Costa A; Mason S; Mayfield J; Moss SJ; Messing RO
    Neuropharmacology; 2022 Dec; 220():109255. PubMed ID: 36152689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.
    Tenor H; Hatzelmann A; Beume R; Lahu G; Zech K; Bethke TD
    Handb Exp Pharmacol; 2011; (204):85-119. PubMed ID: 21695636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model.
    Gu C; Liu J; Qian F; Yu W; Huang D; Shen J; Feng C; Chen K; Li Y; Jiang X; Xu Y; Zhang L
    J Med Chem; 2024 Mar; 67(6):4855-4869. PubMed ID: 38489246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.
    Avila DV; Barker DF; Zhang J; McClain CJ; Barve S; Gobejishvili L
    J Pathol; 2016 Sep; 240(1):96-107. PubMed ID: 27287961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD.
    Wang Y; Wang H; Yang G; Hao Q; Yang K; Shen H; Wang Y; Wang J
    Eur J Med Chem; 2023 Aug; 256():115374. PubMed ID: 37150057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.